Font size

27 January 2020

Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the first patients have been successfully dosed in its phase IIb KHENERGYZE study of Sonlicromanol (previously known as KH176), its wholly-owned lead asset in development to treat a range of mitochondrial diseases.

KHENERGYZE is being initiated at three internationally recognised mitochondrial disease centres in Europe – Radboud University Medical Center, Nijmegen, Netherlands; Newcastle University, United Kingdom and Ludwig-Maximilians-University of Munich, Germany. The double-blind, randomised, placebo-controlled three-way cross-over study examining cognitive function will recruit patients with a specific genetically confirmed DNA mutation in the mitochondrial transfer RNALeu(UUR) (MT-TL1m.3243A>G). This mutation is responsible for MELAS spectrum disorders, including MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) and MIDD (maternally inherited diabetes and deafness) syndromes, and mixed phenotypes.

The study’s primary objective is to evaluate the dose-effect of Sonlicromanol on the attention domain score of cognitive functioning, as assessed by a computerized Cogstate visual identification test. Results are expected in the second half of 2020.

Sonlicromanol is a potentially first-in-class oral small molecule and one of the most advanced disease-modifying drug treatments for mitochondrial disease in development, having shown clinical proof of concept and efficacy, and a well-tolerated safety profile in phase I and IIa studies. It has been granted Orphan Drug Designation for MELAS spectrum disorders, Leigh disease and patients with MIDD in Europe and for all inherited mitochondrial respiratory chain disorders in the USA. 

For the full pressrelease click here

Source: Khondrion

© 2020 Int. Mito Patients